{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:17:49Z","timestamp":1790381869991,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CDC intramural research fund and CDC-Takeda CRADA #D-33-16 fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The development of a safe and effective Zika virus (ZIKV) vaccine has become a global health priority since the widespread epidemic in 2015-2016. Based on previous experience in using the well-characterized and clinically proven dengue virus serotype-2 (DENV-2) PDK-53 vaccine backbone for live-attenuated chimeric flavivirus vaccine development, we developed chimeric DENV-2\/ZIKV vaccine candidates optimized for growth and genetic stability in Vero cells. These vaccine candidates retain all previously characterized attenuation phenotypes of the PDK-53 vaccine virus, including attenuation of neurovirulence for 1-day-old CD-1 mice, absence of virulence in interferon receptor-deficient mice, and lack of transmissibility in the main mosquito vectors. A single DENV-2\/ZIKV dose provides protection against ZIKV challenge in mice and rhesus macaques. Overall, these data indicate that the ZIKV live-attenuated vaccine candidates are safe, immunogenic and effective at preventing ZIKV infection in multiple animal models, warranting continued development.<\/jats:p>","DOI":"10.1038\/s41467-021-27578-w","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T11:07:13Z","timestamp":1639652833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Single dose of chimeric dengue-2\/Zika vaccine candidate protects mice and non-human primates against Zika virus"],"prefix":"10.1038","volume":"12","author":[{"given":"Whitney R.","family":"Baldwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holli A.","family":"Giebler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janae L.","family":"Stovall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-8188","authenticated-orcid":false,"given":"Ginger","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Bohning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansi J.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill A.","family":"Livengood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9720-4792","authenticated-orcid":false,"given":"Claire Y.-H.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"27578_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1602113","volume":"374","author":"LR Petersen","year":"2016","unstructured":"Petersen, L. R., Jamieson, D. J., Powers, A. M. & Honein, M. A. Zika virus. N. Engl. J. Med. 374, 1552\u20131563 (2016).","journal-title":"N. Engl. J. Med."},{"key":"27578_CR2","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1056\/NEJMra1808246","volume":"381","author":"D Musso","year":"2019","unstructured":"Musso, D., Ko, A. I. & Baud, D. Zika virus infection - after the pandemic. N. Engl. J. Med. 381, 1444\u20131457 (2019).","journal-title":"N. Engl. J. Med."},{"key":"27578_CR3","unstructured":"WHO Zika epidemiology update, https:\/\/www.who.int\/emergencies\/diseases\/zika\/zika-epidemiology-update-july-2019.pdf?ua=1 (2019)."},{"key":"27578_CR4","doi-asserted-by":"publisher","unstructured":"Pattnaik, A., Sahoo, B. R. & Pattnaik, A. K. Current status of Zika virus vaccines: successes and challenges. Vaccines 8, https:\/\/doi.org\/10.3390\/vaccines8020266 (2020).","DOI":"10.3390\/vaccines8020266"},{"key":"27578_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34735-7","volume":"8","author":"WR Baldwin","year":"2018","unstructured":"Baldwin, W. R. et al. Purified inactivated Zika vaccine candidates afford protection against lethal challenge in mice. Sci. Rep. 8, 16509 (2018).","journal-title":"Sci. Rep."},{"key":"27578_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60415-6","volume":"10","author":"G Young","year":"2020","unstructured":"Young, G. et al. Complete protection in macaques conferred by purified inactivated Zika vaccine: defining a correlate of protection. Sci. Rep. 10, 3488 (2020).","journal-title":"Sci. Rep."},{"key":"27578_CR7","doi-asserted-by":"crossref","unstructured":"Han H. H., et al. Safety and immunogenicity of a purified inactivated Zika virus vaccine (PIZV) candidate in healthy adults; a randomized, observer-blind phase 1 clinical trial. Lancet Infect. Dis. 21, 1282\u20131292 (2021).","DOI":"10.1016\/S1473-3099(20)30733-7"},{"key":"27578_CR8","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1128\/JVI.79.12.7300-7310.2005","volume":"79","author":"CY Huang","year":"2005","unstructured":"Huang, C. Y., Silengo, S. J., Whiteman, M. C. & Kinney, R. M. Chimeric dengue 2 PDK-53\/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. J. Virol. 79, 7300\u20137310 (2005).","journal-title":"J. Virol."},{"key":"27578_CR9","doi-asserted-by":"publisher","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","volume":"77","author":"CY Huang","year":"2003","unstructured":"Huang, C. Y. et al. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J. Virol. 77, 11436\u201311447 (2003).","journal-title":"J. Virol."},{"key":"27578_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1006\/viro.1997.8500","volume":"230","author":"RM Kinney","year":"1997","unstructured":"Kinney, R. M. et al. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230, 300\u2013308 (1997).","journal-title":"Virology"},{"key":"27578_CR11","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1128\/JVI.74.7.3011-3019.2000","volume":"74","author":"S Butrapet","year":"2000","unstructured":"Butrapet, S. et al. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5\u2019 noncoding region and nonstructural proteins 1 and 3. J. Virol. 74, 3011\u20133019 (2000).","journal-title":"J. Virol."},{"key":"27578_CR12","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","volume":"29","author":"JE Osorio","year":"2011","unstructured":"Osorio, J. E., Huang, C. Y., Kinney, R. M. & Stinchcomb, D. T. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 29, 7251\u20137260 (2011).","journal-title":"Vaccine"},{"key":"27578_CR13","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","volume":"381","author":"S Biswal","year":"2019","unstructured":"Biswal, S. et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N. Engl. J. Med 381, 2009\u20132019 (2019).","journal-title":"N. Engl. J. Med"},{"key":"27578_CR14","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","volume":"395","author":"S Biswal","year":"2020","unstructured":"Biswal, S. et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet 395, 1423\u20131433 (2020).","journal-title":"Lancet"},{"key":"27578_CR15","unstructured":"WHO Reference Cell Banks (RCBs): WHO Vero RCB 10\u201387, https:\/\/www.who.int\/teams\/health-product-policy-and-standards\/standards-and-specifications\/who-reference-cell-banks (2021)."},{"key":"27578_CR16","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1128\/JVI.74.7.3020-3028.2000","volume":"74","author":"CY Huang","year":"2000","unstructured":"Huang, C. Y. et al. Chimeric dengue type 2 (vaccine strain PDK-53)\/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J. Virol. 74, 3020\u20133028 (2000).","journal-title":"J. Virol."},{"key":"27578_CR17","doi-asserted-by":"publisher","first-page":"e2243","DOI":"10.1371\/journal.pntd.0002243","volume":"7","author":"CY Huang","year":"2013","unstructured":"Huang, C. Y. et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl. Trop. Dis. 7, e2243 (2013).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"27578_CR18","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1126\/science.aam7120","volume":"358","author":"L Yuan","year":"2017","unstructured":"Yuan, L. et al. A single mutation in the prM protein of Zika virus contributes to fetal microcephaly. Science 358, 933\u2013936 (2017).","journal-title":"Science"},{"key":"27578_CR19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.4269\/ajtmh.17-0185","volume":"97","author":"EA Dietrich","year":"2017","unstructured":"Dietrich, E. A., Ong, Y. T., Stovall, J. L., Dean, H. & Huang, C. Y. Limited transmission potential of takeda\u2019s tetravalent Dengue vaccine candidate by Aedes albopictus. Am. J. Trop. Med Hyg. 97, 1423\u20131427 (2017).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"27578_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/jmedent\/30.1.233","volume":"30","author":"CJ Mitchell","year":"1993","unstructured":"Mitchell, C. J. et al. Susceptibility parameters of Aedes albopictus to per oral infection with eastern equine encephalitis virus. J. Med. Entomol. 30, 233\u2013235 (1993).","journal-title":"J. Med. Entomol."},{"key":"27578_CR21","doi-asserted-by":"publisher","first-page":"e0004682","DOI":"10.1371\/journal.pntd.0004682","volume":"10","author":"MT Aliota","year":"2016","unstructured":"Aliota, M. T. et al. Characterization of lethal Zika virus infection in AG129 mice. PLoS Negl. Trop. Dis. 10, e0004682 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"27578_CR22","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.celrep.2017.01.056","volume":"18","author":"NK Duggal","year":"2017","unstructured":"Duggal, N. K. et al. Frequent Zika virus sexual transmission and prolonged viral RNA shedding in an immunodeficient mouse model. Cell Rep. 18, 1751\u20131760 (2017).","journal-title":"Cell Rep."},{"key":"27578_CR23","first-page":"242","volume":"67","author":"MP Bradley","year":"2017","unstructured":"Bradley, M. P. & Nagamine, C. M. Animal models of Zika Virus. Comp. Med. 67, 242\u2013252 (2017).","journal-title":"Comp. Med."},{"key":"27578_CR24","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/s41591-018-0088-5","volume":"24","author":"DM Dudley","year":"2018","unstructured":"Dudley, D. M. et al. Miscarriage and stillbirth following maternal Zika virus infection in nonhuman primates. Nat. Med. 24, 1104\u20131107 (2018).","journal-title":"Nat. Med."},{"key":"27578_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12204","volume":"7","author":"DM Dudley","year":"2016","unstructured":"Dudley, D. M. et al. A rhesus macaque model of Asian-lineage Zika virus infection. Nat. Commun. 7, 12204 (2016).","journal-title":"Nat. Commun."},{"key":"27578_CR26","doi-asserted-by":"publisher","first-page":"e0171148","DOI":"10.1371\/journal.pone.0171148","volume":"12","author":"LL Coffey","year":"2017","unstructured":"Coffey, L. L. et al. Zika virus tissue and blood compartmentalization in acute infection of Rhesus Macaques. PLoS One 12, e0171148 (2017).","journal-title":"PLoS One"},{"key":"27578_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04056-4","volume":"9","author":"DM Magnani","year":"2018","unstructured":"Magnani, D. M. et al. Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques. Nat. Commun. 9, 1624 (2018).","journal-title":"Nat. Commun."},{"key":"27578_CR28","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/nm.4206","volume":"22","author":"CE Osuna","year":"2016","unstructured":"Osuna, C. E. et al. Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat. Med. 22, 1448\u20131455 (2016).","journal-title":"Nat. Med."},{"key":"27578_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0161-7","volume":"7","author":"F Touret","year":"2018","unstructured":"Touret, F. et al. Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone. Emerg. Microbes Infect. 7, 161 (2018).","journal-title":"Emerg. Microbes Infect."},{"key":"27578_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0092-2","volume":"3","author":"DB Kum","year":"2018","unstructured":"Kum, D. B. et al. A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice. NPJ Vaccines 3, 56 (2018).","journal-title":"NPJ Vaccines"},{"key":"27578_CR31","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1128\/JVI.02458-10","volume":"85","author":"R Fritz","year":"2011","unstructured":"Fritz, R. et al. The unique transmembrane hairpin of flavivirus fusion protein E is essential for membrane fusion. J. Virol. 85, 4377\u20134385 (2011).","journal-title":"J. Virol."},{"key":"27578_CR32","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1128\/JVI.02882-14","volume":"89","author":"X Xie","year":"2015","unstructured":"Xie, X., Zou, J., Puttikhunt, C., Yuan, Z. & Shi, P.-Y. Two distinct sets of NS2A molecules are responsible for Dengue virus RNA synthesis and virion assembly. J. Virol. 89, 1298\u20131313 (2015).","journal-title":"J. Virol."},{"key":"27578_CR33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/vbz.2010.0150","volume":"11","author":"A Brault","year":"2011","unstructured":"Brault, A. et al. Replication of the primary dog kidney-53 dengue 2 virus vaccine candidate in Aedes aegypti is modulated by a mutation in the 5\u2019 untranslated region and amino acid substitutions in nonstructural proteins 1 and 3. Vector Borne Zoonotic Dis. 11, 683\u2013689 (2011).","journal-title":"Vector Borne Zoonotic Dis."},{"key":"27578_CR34","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/infdis\/169.3.512","volume":"169","author":"A Jennings","year":"1994","unstructured":"Jennings, A. et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J. Infect. Dis. 169, 512\u2013518 (1994).","journal-title":"J. Infect. Dis."},{"key":"27578_CR35","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1128\/JVI.76.4.1932-1943.2002","volume":"76","author":"T Monath","year":"2002","unstructured":"Monath, T. et al. Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J. Virol. 76, 1932\u20131943 (2002).","journal-title":"J. Virol."},{"key":"27578_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00282-y","volume":"6","author":"WX Chin","year":"2021","unstructured":"Chin, W. X. et al. A single-dose live attenuated chimeric vaccine candidate against Zika virus. NPJ Vaccines 6, 20 (2021).","journal-title":"NPJ Vaccines"},{"key":"27578_CR37","doi-asserted-by":"publisher","unstructured":"Abbink, P. et al. Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci. Transl. Med. 9, https:\/\/doi.org\/10.1126\/scitranslmed.aao4163 (2017).","DOI":"10.1126\/scitranslmed.aao4163"},{"key":"27578_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(17)33106-9","volume":"391","author":"K Modjarrad","year":"2018","unstructured":"Modjarrad, K. et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet 391, 563\u2013571 (2018).","journal-title":"Lancet"},{"key":"27578_CR39","doi-asserted-by":"publisher","unstructured":"Salisch, N. C. et al. A double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an Ad26-vectored anti-Zika virus vaccine. Ann. Intern. Med., https:\/\/doi.org\/10.7326\/M20-5306 (2021).","DOI":"10.7326\/M20-5306"},{"key":"27578_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00234-y","volume":"5","author":"N Berry","year":"2020","unstructured":"Berry, N. et al. Passive immunisation of convalescent human anti-Zika plasma protects against challenge with New World Zika virus in cynomolgus macaques. NPJ Vaccines 5, 86 (2020).","journal-title":"NPJ Vaccines"},{"key":"27578_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ebiom.2017.12.010","volume":"27","author":"D Espinosa","year":"2018","unstructured":"Espinosa, D. et al. Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge. EBioMedicine 27, 61\u201370 (2018).","journal-title":"EBioMedicine"},{"key":"27578_CR42","doi-asserted-by":"publisher","unstructured":"Tebas, P. et al. Safety and immunogenicity of an anti-Zika virus DNA vaccine - preliminary report. N. Engl. J. Med., https:\/\/doi.org\/10.1056\/NEJMoa1708120 (2017).","DOI":"10.1056\/NEJMoa1708120"},{"key":"27578_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/srep46375","volume":"7","author":"K Sumathy","year":"2017","unstructured":"Sumathy, K. et al. Protective efficacy of Zika vaccine in AG129 mouse model. Sci. Rep. 7, 46375 (2017).","journal-title":"Sci. Rep."},{"key":"27578_CR44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/978-981-10-8727-1_17","volume":"1062","author":"L Rivino","year":"2018","unstructured":"Rivino, L. Understanding the human T cell response to Dengue virus. Adv. Exp. Med. Biol. 1062, 241\u2013250 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"27578_CR45","doi-asserted-by":"publisher","unstructured":"Subramaniam, K. S. et al. Two is better than one: evidence for T-cell cross-protection between Dengue and Zika and implications on vaccine design. Front. Immunol. 11, https:\/\/doi.org\/10.3389\/fimmu.2020.00517 (2020).","DOI":"10.3389\/fimmu.2020.00517"},{"key":"27578_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01669-z","volume":"8","author":"J Wen","year":"2017","unstructured":"Wen, J. et al. Dengue virus-reactive CD8(+) T cells mediate cross-protection against subsequent Zika virus challenge. Nat. Commun. 8, 1459 (2017).","journal-title":"Nat. Commun."},{"key":"27578_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05458-0","volume":"9","author":"JA Regla-Nava","year":"2018","unstructured":"Regla-Nava, J. A. et al. Cross-reactive Dengue virus-specific CD8(+) T cells protect against Zika virus during pregnancy. Nat. Commun. 9, 3042 (2018).","journal-title":"Nat. Commun."},{"key":"27578_CR48","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3389\/fimmu.2019.01778","volume":"10","author":"AT Waickman","year":"2019","unstructured":"Waickman, A. T. et al. Assessing the diversity and stability of cellular immunity generated in response to the candidate live-attenuated dengue virus vaccine TAK-003. Front Immunol. 10, 1778 (2019).","journal-title":"Front Immunol."},{"key":"27578_CR49","doi-asserted-by":"publisher","unstructured":"Grifoni, A. et al. T cell responses induced by attenuated flavivirus vaccination are specific and show limited cross-reactivity with other flavivirus species. J. Virol. 94, https:\/\/doi.org\/10.1128\/jvi.00089-20 (2020).","DOI":"10.1128\/jvi.00089-20"},{"key":"27578_CR50","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.abb6143","volume":"369","author":"LC Katzelnick","year":"2020","unstructured":"Katzelnick, L. C. et al. Zika virus infection enhances future risk of severe dengue disease. Science 369, 1123\u20131128 (2020).","journal-title":"Science"},{"key":"27578_CR51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coviro.2020.08.006","volume":"43","author":"LC Katzelnick","year":"2020","unstructured":"Katzelnick, L. C., Bos, S. & Harris, E. Protective and enhancing interactions among dengue viruses 1-4 and Zika virus. Curr. Opin. Virol. 43, 59\u201370 (2020).","journal-title":"Curr. Opin. Virol."},{"key":"27578_CR52","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/infdis\/jiz081","volume":"221","author":"M Sharma","year":"2019","unstructured":"Sharma, M. et al. Magnitude and functionality of the NS1-specific antibody response elicited by a live-attenuated tetravalent dengue vaccine candidate. J. Infect. Dis. 221, 867\u2013877 (2019).","journal-title":"J. Infect. Dis."},{"key":"27578_CR53","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.virol.2009.10.027","volume":"396","author":"CY Huang","year":"2010","unstructured":"Huang, C. Y. et al. The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion. Virology 396, 305\u2013315 (2010).","journal-title":"Virology"},{"key":"27578_CR54","doi-asserted-by":"publisher","first-page":"e0005101","DOI":"10.1371\/journal.pntd.0005101","volume":"10","author":"J Weger-Lucarelli","year":"2016","unstructured":"Weger-Lucarelli, J. et al. Vector competence of American mosquitoes for three strains of Zika virus. PLOS Neglected Tropical Dis. 10, e0005101 (2016).","journal-title":"PLOS Neglected Tropical Dis."},{"key":"27578_CR55","doi-asserted-by":"publisher","first-page":"e0250516","DOI":"10.1371\/journal.pone.0250516","volume":"16","author":"K Bohning","year":"2021","unstructured":"Bohning, K. et al. A high throughput reporter virus particle microneutralization assay for quantitation of Zika virus neutralizing antibodies in multiple species. PLoS One 16, e0250516 (2021).","journal-title":"PLoS One"},{"key":"27578_CR56","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3201\/eid1408.080287","volume":"14","author":"RS Lanciotti","year":"2008","unstructured":"Lanciotti, R. S. et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14, 1232\u20131239 (2008).","journal-title":"Emerg. Infect. Dis."},{"key":"27578_CR57","doi-asserted-by":"publisher","unstructured":"Merkes, C. et al. Reporting the limits of detection (LOD) and quantification (LOQ) for environmental DNA assays. Code: U.S. Geological Survey data release, https:\/\/doi.org\/10.5066\/P9AKHU1R (2019).","DOI":"10.5066\/P9AKHU1R"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27578-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27578-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27578-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T19:08:55Z","timestamp":1676056135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27578-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["27578"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27578-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]},"assertion":[{"value":"25 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.Y., K.J.B., H.J.D., J.A.L., W.R.B., and H.A.G. are employees of Takeda. H.A.G. and W.R.B. were contracted by Takeda as CDC guest researchers during the study. C.Y.H.\u2019s laboratory received CRADA fund provided by Takeda to partly support the study. C.Y.H. is an inventor of CDC patent applications based on DENV-2 PDK-53 based chimeric flavivirus vaccines, including the D2\/ZIKV and TDV vaccines (TDV is licensed to Takeda for commercial development). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7320"}}